Semaglutide, Muscle Loss, and the Protein Question

Key Finding Absolute skeletal muscle mass declined with semaglutide, but age- and BMI-referenced muscle status improved, and absolute handgrip strength was preserved — the two lenses tell different stories.

The question of what GLP-1 receptor agonists do to muscle has mostly been answered with anecdotes. Two recent papers try to answer it with data — one longitudinal study measuring what actually happens to body composition and strength on semaglutide, and one clinical review of the dietary mechanism most likely to matter: protein intake.

The measurement study

A 12-month retrospective study from a routine obesity clinic in Barcelona compared patients in a lifestyle education program (n = 39) with those adding semaglutide (n = 44). Body composition came from bioelectrical impedance, strength from handgrip dynamometry, and resting energy expenditure from indirect calorimetry [PMID 42640861].

The semaglutide group lost more — about 11 kg versus the lifestyle group, with larger drops in BMI and waist circumference. Lean tissue fell too: skeletal muscle mass went from 29.9 to 28.7 kg and fat-free mass from 53.8 to 52.7 kg, both statistically significant within the semaglutide group. On the surface, that is the feared outcome: absolute muscle loss during weight loss.

But the study also scored muscle status against an age- and BMI-referenced standard (SMI-SDS, validated against MRI-derived reference data). On that lens, the semaglutide group improved markedly (delta 0.52 versus 0.09 in the lifestyle group), and absolute handgrip strength was preserved in both groups while relative handgrip strength improved with semaglutide. The authors describe it as qualitative muscle optimization alongside absolute lean tissue loss — a body that lost weight and fat while its muscle kept up relative to what would be expected for age and size.

Resting energy expenditure fell in both groups, and part of the decline exceeded what body-composition changes alone would predict — the phenomenon known as adaptive thermogenesis. The magnitude did not differ significantly between the semaglutide and lifestyle groups.

The protein question

The second paper attacks the mechanism from the dietary side. In a review in Advances in Therapy, researchers summarize the evidence on protein intake during incretin-based therapy and its implications for older adults [PMID 42631799]. The core argument: these drugs reduce intake by suppressing appetite, and reduced total energy almost necessarily reduces absolute protein unless the diet is deliberately constructed otherwise.

Randomized trials with liraglutide suggest protein is broadly maintained as a proportion of total energy — roughly 14 to 18 percent — but that does not settle the question, because a preserved proportion of a much smaller total can leave absolute protein below the level needed to drive muscle protein synthesis, especially in older adults with anabolic resistance. The review’s blunt conclusion is that comprehensive dietary data are scarce, and few studies have tied intake changes to measurable declines in muscle mass, strength, or performance.

What to make of both

Taken together, the two papers frame the muscle question more honestly than either alone. The measurement study suggests that for a general obesity clinic population, semaglutide’s lean-tissue losses look more like the expected accompaniment of substantial fat loss than like disproportionate wasting — strength held, and reference-based muscle status improved. But that tells us little about the person already under-muscled, older, or eating well below protein needs, which is exactly the population the review warns about.

The practical synthesis is unglamorous: track protein during treatment, especially in older adults; treat muscle strength as an outcome worth measuring; and do not read a drop on the bathroom scale as a drop in muscle without looking at composition and function. Longer trials that pair detailed dietary assessment with body composition and functional outcomes — the review’s explicit ask — are what will settle this.

For compound-level reference records covering preparation and administration, see the Semaglutide reference record and the Tirzepatide reference record on ResearchProtocols.